News and Comments

EXELEXIS: The Importance Of The Public Offering. XOMA: What Should We Do Now?

  Thursday, July 23, 2015

Why the financing through a secondary public offering was a must for Exelixis?  More...

Xoma: Phase 3 EYEGUARD-B Trial is Good News For Gevokizumab

  Wednesday, May 27, 2015

Xoma (XOMA) announced good news from Phase 3 EYEGUARD-B trial of its monoclonal antibody drug gevokizumab for Behcet’s uveitis. The study, which is sponsored by Xoma’s development partner Servier, reached its target exacerbation event as specified in the study design.  More...

Xoma: New Plans That Can Bring Hope

  Monday, January 23, 2012

Thursday’s news brought to mind our old friend, Xoma (XOMA), which, unlike Raymond, not everybody loves it. Actually, many still love Xoma, but with reservation and resentment. Many time we questioned whether Xoma is addictive. For a couple of months, when we had nothing to write, good or bad, about Xoma, readers accused us of infidelity. It is important to mention that two decades ago, many investors highly treasured Xoma, viewing it as the personification of hope for breakthrough drugs the budding biotechnology industry was promising to get across to medical practice. In London, investors asked us if we know Xoma and the same came about in Paris, Milan, Rome, and Zurich. As a matter of fact, this firm was esteemed everywhere for its technologies, scientists, and pipeline products. More...


  Tuesday, January 11, 2011

The tale, this time, is not about London and Paris and is not written by Charles Dickens in 1859. It is about two biotech firms, Xoma (XOMA) and Elan (ELN), written by the market in the 21st century. The similarity between the old and the new tales is the furry the constituents of the two cities and companies have against their rulers’ mismanagement.  More...

XOMA: Was the Rally really A surprise?

  Wednesday, December 22, 2010

Xoma (XOMA) soared yesterday on no news from the company. Early afternoon, Reuters put out a press release stating that the rally occurred on high expectations of the mid-stage results of XOMA 052 in the treatment of diabetes. To read the article, please click or copy and paste the link: More...

XOMA (XOMA): What would erase investors’ reservations?

  Thursday, November 11, 2010

According to data from its IL-1 beta inhibitor drug Xoma 052 in patients with uveitis, all seven patients with Behcet's uveitis enrolled in the XOMA 052 trial experienced rapid reduction of intraocular inflammation and improvement in visual acuity following a single treatment with the drug. A recent data presented at the 2010 American College of Rheumatology Scientific meeting demonstrate that all the five patients re-treated with XOMA 052 due to a recurring uveitis exacerbation have responded all over again to XOMA 052 and maintained their response for several months. Cytokine data showed reduced levels of IL-1 beta, IL-1 alpha and IL-6, as compared to baseline, with an increase in the levels of interferon gamma, which protects against infection.  More...

XOMA: Past, Present and Future.

  Tuesday, February 09, 2010

The firm has encouraging news today. But recently the firm’s stock plummeted for reasons not related to the firm’s technological capabilities, but to a mixture of inherited consequences of bad financial decisions, past unethical behavior and, in some circumstances, bad luck. Investors’ agitation - well reflected in their exaggerated reactions towards some of the firm’s unfortunate news, has also contributed to the stock’s plummeting. The negative chain reaction began a few years ago when Xoma’s investigational drug for sepsis failed to pass the approval test even though it saved children’s lives in clinical trials. The company decided to abandon the drug years before investors learn the news that was never announced. A couple of years after the firm has shelved the drug, investors realized that the drug is not existing in longer in Xoma’s pipeline.  More...

Recent Postings



ACADIA (ACAD) Rapamune Illumina (ILMN) Zerenex Ariad (ARIA) ISIS (ISIS) Telaprevir Micromet (MITI) Roche (RHHBY) KITE (KITE) INNOVIVA (INVA) ZALTRAP™ MODERNA Revlimid (lenolidamide) Ziofpharm (ZIOP) JUNO (JUNO) Regeneron (REGN) GlaxoSmithKline (GSK) AERIE PHARMACEUTICALS Endometrial Cancer Intercept (ICPT) Advaxis (ADXS) RenenxBio (RGNX) Anadys (ANDS) Elan (ELN) Intrexon (XON) ADVENTRIX (ANX) Prolor Biotech (PBTH) Epizyme (EPZM) OncoCyte (OCX) Exelixis (EXEL) VANDA (VNDA) Theravance Bio Pharma (TBPH) ABBVIE (ABBV) Spike Therapeutics (ONCE) Trastuzumab-DM1 Multiple Myeloma galapagos (GLPG) Sanofi (SNA) Jazz Pharmaceuticals (JAZZ) PORTOLA (PTLA) Ridaforolimus Gilead (GILD) GUARDIAN HEALTH Agenus (AGEN) C4 Therapeutics SYNTA (SNTA) Incyte (INCY) Prosensa (RNA) Array Pharmaceuticals (ARRY) Sequenom (SQNM) Anacor (ANAC) AstraZeneca (AZN) KERYX (KERX) Human Genome Sciences (HGSI) Adaptimmune (ADAP) CRISPR Therapeutics (CRSP) LEXICON (LXRX) Inovio (INO) Biocryst (BCRX) NEKTAR (NKTR)) Alnylam (ALNY) Amgen (AMGN) Ocular Therapeutix (OCUL) NANTKWEST (NK) ARGOS (ARGS) Editas (EDIT) Vitae Pharmaceuticals (VTAE) AGOS (ARGS) OSI (OSIP) CEMPRA (CEMP) Sangamo (SGMO) Human Longevity (HLI) Global Cell Therapeutics (GBT) Biogen Idec (BIIB) NOVOCURE (NVCR) HALOZYME (HALO) Tysabri Ionis (IONS) GlycoMimetics (GLYN) Sanofi (SNY) Herceptin Sanofi-Aventis (SAN) SUNESIS PHARMACEUTICALS (SNSS) Merck (MRK) Pluristem (PSTI) BIOMARIN (BMRN) TOKAI (TKAOI) Vertex (VRTX) Aimmune Therapeutics (AIMT) Galena (GALE) Dynavax (DVAX) CompuGen (CGEN) ImmunoGen (IMGN) Alder Biopharmaceuticals (ALDR) Agenus (AGEN Dendreon (DNDN) Bellicum (BLCM) Cytokinetics (CYTK) Xoma (XOMA) Idenix (IDIX) Mirati Therapeutics (MRTX) Sarepta (SRPT) Abbott Laboratories (ABT) JOUNCE THERAPEUTICS (JNCE) IDERA (IDRA) Akebia Therapeutics (AKAB) Valeant Pharmaceuticals International (VRX) Auspex (ASPX) SERES THERAPEUTICS (MCRB) Benlysta (belimumab) PTC Therapeutics (PTCT) Bristol-Myers Squibb (BMY) Roche (ROCHE) Onyx (ONXX) REGULUS (RGLS) Seattle Genetics (SGEN) ARCA (ABIO) Genentech Velcade (bortezomib) Theravance (THRX) Intermune (ITMN) NEUROCRINE (NBIX)